Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4716-4727

  Younes, Maher Nabil ^a   Yigitbasi, Orhan Gazi ^a   Park, Young Wook ^a   Kim, Sun Jin ^a   Jasser, Samar A ^a   Hawthorne, Valerie Stone ^a   Yazici, Yasemin Dakak ^a   Mandal, Mahitosh ^a   Bekele, Benjamin Nebiyou ^a   Bucana, Corazon D ^a   Fidler, Isaiah J ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG INHIBITION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RECEPTOR BLOCKING; THYROID FOLLICULAR CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE NEOPLASMS; CELL PROLIFERATION; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PURINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 21144442649     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4196     Document Type: Article

References (60)

1. Correa P, Chen VW. Endocrine gland cancer. Cancer 1995;75:338-52.
2. Jemal A, Tiwari RC, Murray T. et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
3. Sherman SI. Thyroid carcinoma Lancet 2003:361:501-11.
4. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation Study. Cancer 2000; 89:202-17.
5. Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 1999:9: 1227-35.
6. Schlumberger MJ. Papillary and follicular thyroid carcinoma, N Engl J Med 1998;338:297-306.
7. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986:63;960-7.
8. DeGroot LJ, Kaplan EL, Sliukla MS, Salti G, Straus FH. Morbidity and mortality In follicular thyroid cancer. J Clin Endocrinol Metab 1995;80:2946-53.
9. Marcocci C. Pacini F, Elisei R, et al. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 1989:106:960-6.
10. Roodman GD. Mechanisms of bone metastasis, N Engl J Med 2004:350:1655-64.
11. Tubiana M, Haddad E, Schlumberger M, Hill C, Rougier P, Sarrazin D. External radiotherapy in thyroid cancers, Cancer 1985;55:2062-71.
12. Smit JW, Vielvoye GJ, Goslings BM. Embolizatlon for vertebral metastases of follicular thyroid carcinoma, J Clin Endocrinol Metab 2000;85:989-94.
13. Menzel C, Grunwald F, Schomburg A. et al. "High-dose" radiolodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996;37:1496-503.
14. Dinneen SF, Vallmaki MJ, Bergstralh EJ, et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995;80:2041-5.
15. Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling leads to Inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003:63: 2940-7.
16. Tuttle M, Robbins R, Larson SM, Strauss HW. Challenging cases in thyroid cancer; a multidisciplinary approach. Eur J Nucl Med Mol Imaging 2004:31: 605-12.
17. Zettinig G, Fueger BJ, Passler C, et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma-surgery or conventional therapy? Clin Endocrinol (Oxf) 2002; 56:377-82.
18. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR. Co-expression of the genes encoding transforming growth factor-α and its receptor in papillary carcinomas of the thyroid. Int J Cancer 1990;46:382-7.
19. Holting T, Siperstein AE, Clark OH, Duh QY. Epidermal growth factor (EGF)- and transforming growth factor α-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase In vitro, Eur J Endocrinol 1995;132:229-35.
20. Gorgoulis V, Aninos D, Priftis C, et al. Expression of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in thyroid tumors, In vivo 1992:6:291-6.
21. Soh EY, Eigelberger MS, Kim KJ, et al. Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth In vivo. Surgery 2000:128: 1059-65;discussion 1065-56.
22. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumoriSgenesis, Cell 1996;86:353-64.
23. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression Is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997;82:3741-7.
24. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-76.
25. Tuttle RM, Fleisher M, Francis GL, Robbins RJ. Serum vascular endothelial growth factor levels are elevated In metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002;87:1737-42.
26. Ishiwata T, Iino Y, Takel H, Oyama T, Morishita Y. Tumor angiogenesis as an independent prognostic indicator in human papillary thyroid carcinoma. Oncol Rep 1998;5:1343-6.
27. Ye C, Feng C, Wang S, et al. sFlt-1 gene therapy of follicular thyroid carcinoma. Endocrinology 2004;145: 817-22.
28. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584. a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study, Endocrinology 2004;145:1031-8.
29. Ye C, Feng C, Wang S. Liu X Lin Y, Li M. Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 2002;143: 3522-8.
30. Traxler P. Allegrini PR, Brandt R. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931-41.
31. Yigitbasi OG, Younes MN, Doan DD, et al. Tumor and endothelial cell therapy of oral cancer by dual tyrosine receptor blockade. Cancer Res 2004;64:7977-84.
32. Estour B. Van Herle AJ, Juillard GJ, et al. Characterization of a human follicular thyroid carcinoma cell line (UCLA RO 82 W-1). Virchows Arch B Cell Pathol Incl Mol Pathol 1989;57:167-74.
33. Holsinger FC, Doan DD, Jasser SA, et al. Epidermal growth factor receptor blockade potentiates apoptosis mediated by paclitoxel and leads to prolonged survival in a murine model of oral cancer. Clin Cancer Res 2003;9:3183-9.
34. Bruns CJ, Solorzano CC, Horbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase Inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
35. Lynch TJ, Bell DW. Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
36. Kim SJ, Uehara H, Yazici S, et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of poclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004;64:4201-6.
37. Mori S. Sawai T, Teshima T, Kyogoku M. A new decalcifying technique for immunohistochemical studies of calcified tissue, especially applicable to cell surface marker demonstration. J Histochem Cytochem 1988;36:111-4.
38. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002; 62:1996-2003.
39. Uehara H, Kim SJ, Karashima T. et al. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst 2003;95:458-70.
40. Inaba M, Umemura S, Satoh H, et al. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type. Pathol Int 2003;53:146-53.
41. Schiff B, McMurphy A, Jasser S, et al. Epidermal growth factor receptor (EGF-R) is overexpressed in anaplastic thyroid cancer, and the EGF-R inhibitor gefitinib ("Iressa," ZD 1839) inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 2004;10: 8594-602.
42. Bergstrom JD, Westermark B, Heldin NE. Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells, Exp Cell Res 2000;259:293-9.
43. Roodman GD. Biology of osteoclast activation in cancer, J Clin Oncol 2001;19:3562-71.
44. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothellal cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice, Clin Cancer Res 2003;9:1200-10.
45. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475-80.
46. Weidner N, Semple JP, Welch WR, Folkman J, Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
47. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997;89:881-6.
48. Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma, Clin Cancer Res 2000;6:4874-84.
49. Poulaki V, Mitsiades CS, McMullan C, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab 2003;88:5392-8.
50. Vella V, Sciacca L, Pandini G, et al. The IGF system in thyroid cancer: new concepts. Mol Pathol 2001;54: 121-4.
51. Saito J, Kohn AD, Roth RA, et al. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 2001;11:339-51.
52. Mitsiades CS, Poulaki V. Mitsiades N. Insulin-like growth factor (IGF)-l protects thyroid carcinoma cells from TRAIL-induced apoptosis. Proc Am Assoc Cancer Res 2001;42:272.
53. Yashiro T, Ohba Y, Murakami H, et al. Expression of insulin-like growth factor receptors In primary human thyroid neoplasms. Acta Endocrinol (Copenh) 1989;121: 112-20.
54. Vasko V. Saji M Hardy E, et al. Akt activation and localisation correlate with tumour invasion and oncogens expression In thyroid cancer. J Med Genet 2004;41: 161-70.
55. Ringel MO, Hayre N, Salto J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-11.
56. Mandal M, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer. In press 2005.
57. Chen KT, Lin JD, Chao TC, et al. Identifying differentially expressed genes associated with metastasis of follicular thyroid cancer by cDNA expression array. Thyroid 2001;11:41-6.
58. Lemoine NR, Mayall ES. Wyllie FS, et al. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989;4: 159-64.
59. Specht MC, Barden CB, Fahey TJ III. p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 2001;130:936-40.
60. Park YW, Younes MN, Jasser SA. et al. AEE788, a dual tyrosine kinase inhibitor of EGFR and VEGFR, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res 2005;11:1963-73.